Aripiprazole NDC 43598-734

NDC codes

FDA NDC Directory

Product NDC (as listed)43598-734Labeler and product segments. Claims need a package NDC.

Product NDC at billing width43598-0734Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
43598-734-30	43598073430	30 TABLET in 1 BOTTLE (43598-734-30)Marketed from May 15, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Aripiprazole
Generic name (nonproprietary): aripiprazole orally disintegrating
Active ingredients: Aripiprazole — 15 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Dr. Reddy's Laboratories Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207240
Marketing start: May 15, 2018
Listing expires: Dec 31, 2027
Identifiers: Product ID 43598-734_9a1950c0-9796-4dc8-8ec0-47ef2d287c48SPL ID 9a1950c0-9796-4dc8-8ec0-47ef2d287c48SPL set ID 394ea4a4-3991-4f98-b38f-56e9335d66b3RxCUI 643019, 643022UNII 82VFR53I78UPC 0343598733302, 0343598734309
Pharmacologic class: Atypical Antipsychotic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N443598073430 followed by a unit qualifier and the quantity

Package 43598-0734-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 21, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Aripiprazole orally disintegrating tablets are indicated for the treatment of: Schizophrenia [see Clinical Studies (14.1) ] Irritability Associated with Autistic Disorder [see Clinical Studies (14.4) ] Treatment of Tourette’s Disorder [see Clinical Studies (14.5) ] Aripiprazole is an atypical antipsychotic. The oral formulation is indicated for: Schizophrenia ( 14.1 ) Irritability Associated with Autistic Disorder ( 14.4 ) Treatment of Tourette’s disorder ( 14.5 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207240

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207240
Product	Strength	Form · route	Labeler	Product NDC
Aripiprazolearipiprazole orally disintegrating	Aripiprazole 10 mg/1	TabletOral	ScieGen Pharmaceuticals Inc	50228-330
Aripiprazolearipiprazole orally disintegrating	Aripiprazole 15 mg/1	TabletOral	ScieGen Pharmaceuticals Inc	50228-331
Aripiprazolearipiprazole orally disintegrating	Aripiprazole 10 mg/1	TabletOral	Dr. Reddy's Laboratories Inc	43598-733

Aripiprazole (aripiprazole orally disintegrating) NDC 43598-734